Biography and Research Information

OverviewAI-generated summary

Steven W. Barger is a Professor at the University of Arkansas for Medical Sciences whose research focuses on the molecular mechanisms underlying neurodegenerative diseases, particularly Alzheimer's disease. His work investigates the role of cellular processes such as autophagy, lysosomal function, and glucose transport in disease pathogenesis and progression. Barger has led research groups and secured federal funding to study compromised glial glucose transporter function in aging and Alzheimer's disease, as well as the broader role of glucose transport in the disease's development.

His recent publications explore various therapeutic strategies and molecular targets for neurodegeneration. These include the rescue of autophagic failure in Alzheimer's disease using small molecules, the development of inhibitors for system xC− transport to reduce microglial glutamate release and neurotoxicity, and the investigation of thiadiazolidinone analogs for their potential to inhibit aggregation-mediated pathology and extend lifespan in neurodegeneration models. Barger also examines the relationship between specific genetic factors, like ApoE4, and cellular dysfunction, as well as the potential impact of prescription drug use on Alzheimer's risk.

With a career marked by extensive publication and significant citation impact (h-index: 49, 10,231 citations), Barger has received federal funding totaling $747,250 from the NIH/National Institute on Aging for his research. He actively collaborates with researchers at the University of Arkansas at Little Rock and within the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 49
  • Publications: 144
  • Citations: 10,231

Selected Publications

  • Impact of P-Glycoprotein Substrates on Transendothelial Transport of Amyloid-β Peptide (2025) DOI
  • Prescription-based association of P-glycoprotein substrates with Alzheimer's disease risk: A nested case-control study (2025) DOI
  • P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities (2025) DOI
  • Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer’s disease by targeted small molecules (2024) DOI
  • Design, synthesis, and characterization of novel system xC− transport inhibitors: inhibition of microglial glutamate release and neurotoxicity (2023) DOI
  • Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023) DOI
  • Central repeat fragment of reelin leads to active reelin intracellular signaling and rescues cognitive deficits in a mouse model of reelin deficiency (2023) DOI
  • Design, synthesis, and characterization of novel Xc- transport inhibitors: Inhibition of microglial glutamate release and neurotoxicity (2023) DOI
  • Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype (2023) DOI
  • Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis (2022) DOI
  • Glucose transport in the regulation of T-cell activation: the journey may be as important as the destination (2022) DOI
  • Serine Racemase Expression Differentiates Aging from Alzheimer’s Brain (2022) DOI
  • Amyloid β-peptide impacts on glucose regulation are dependent on apolipoprotein E genotype (2022) DOI

Federal Grants 2 $747,250 total

NIH/National Institute on Aging Contact PI Apr 2023 - Mar 2028

Role of glucose transport in Alzheimer's disease pathogenesis

National Institute on Aging $374,850 R01
NIH/National Institute on Aging Contact PI Apr 2021 - Dec 2026

Compromised function of a glial glucose transporter in aging and Alzheimer's disease

National Institute on Aging $372,400 R01

Grants & Funding

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics